title: Non-congenital heart disease associated pediatric pulmonary arterial hypertension.
abstract: Recognition of causes of pulmonary hypertension other than congenital heart disease is increasing in children. Diagnosis and treatment of any underlying cause of pulmonary hypertension is crucial for optimal management of pulmonary hypertension. This article discusses the available knowledge regarding several disorders associated with pulmonary hypertension in children: idiopathic pulmonary arterial hypertension (IPAH), pulmonary capillary hemangiomatosis, pulmonary veno-occlusive disease, hemoglobinopathies, hepatopulmonary syndrome, portopulmonary hypertension and HIV. Three classes of drugs have been extensively studied for the treatment of IPAH in adults: prostanoids (epoprostenol, treprostinil, iloprost, beraprost), endothelin receptor antagonists (bosentan, sitaxsentan, ambrisentan), and phosphodiesterase inhibitors (Sildenafil, tadalafil). These medications have been used in treatment of children with pulmonary arterial hypertension, although randomized clinical trial data is lacking. As pulmonary vasodilator therapy in certain diseases may be associated with adverse outcomes, further study of these medications is needed before widespread use is encouraged.
authors.affiliation: University of Colorado Denver School of Medicine and The Children's Hospital, United States.
authors.forename: D D
authors.initials: DD
authors.lastname: Ivy
authors.forename: J A
authors.initials: JA
authors.lastname: Feinstein
authors.forename: T
authors.initials: T
authors.lastname: Humpl
authors.forename: E B
authors.initials: EB
authors.lastname: Rosenzweig